Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia

Cancer

Volumn 120, Issue 12, 2014, Pages 1838-1846

  Giagounidis, Aristoteles ^a   Mufti, Ghulam J ^b   Fenaux, Pierre ^c   Sekeres, Mikkael A ^d   Szer, Jeffrey ^e   Platzbecker, Uwe ^f   Kuendgen, Andrea ^g   Gaidano, Gianluca ^h   Wiktor Jedrzejczak, Wieslaw ⁱ   Hu, Kuolung ^j   Woodard, Paul ^j   Yang, Allen S ^j   Kantarjian, Hagop M ^k  

^a MARIEN HOSPITAL DÜSSELDORF   (Germany)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c AVICENNE HOSPITAL   (France)

^d TAUSSIG CANCER INSTITUTE   (United States)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

^f UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^g UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^h Amedeo Avogadro University   (Italy)

ⁱ MEDICAL UNIVERSITY OF WARSAW   (Poland)

^j AMGEN INC   (United States)

^k UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

drug therapy; myelodysplastic syndromes; randomized controlled trial; romiplostim; thrombocytopenia

Indexed keywords

PLACEBO; ROMIPLOSTIM;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLAST CELL; BLEEDING; CANCER RISK; CELL COUNT; COLON CANCER; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; FEVER; HEMATOMA; HUMAN; INCIDENCE; INTERMEDIATE RISK PATIENT; LEUKOCYTOSIS; LOW RISK PATIENT; MALE; MYELOBLAST; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OVERALL SURVIVAL; PETECHIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SPLEEN INFARCTION; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT RESPONSE;

DRUG THERAPY; MYELODYSPLASTIC SYNDROMES; RANDOMIZED CONTROLLED TRIAL; ROMIPLOSTIM; THROMBOCYTOPENIA;

AGED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PLACEBOS; RECEPTORS, FC; RECOMBINANT FUSION PROTEINS; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; THROMBOPOIETIN; TREATMENT OUTCOME;

EID: 84902192838     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28663     Document Type: Article

References (28)

1. Garcia-Manero G, Shan J, Faderl S, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia. 2008; 22: 538-543.
2. Gonzalez-Porras J, Cordoba I, Such E, et al. Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome. Cancer. 2011; 117: 5529-5537.
3. Kantarjian H, Giles F, List A, et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer. 2007; 109: 1705-1714.
4. Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008; 113: 1351-1361.
5. Sekeres MA, Schoonen WM, Kantarjian H, et al. Characteristics of US patients with myelodysplastic syndromes: results of 6 cross-sectional physician surveys. J Natl Cancer Inst. 2008; 100: 1542-1551.
6. Manoharan A, Brighton T, Gemmell R, et al. Platelet dysfunction in myelodysplastic syndromes: a clinicopathological study. Int J Hematol. 2002; 76: 272-278.
7. Mittelman M, Zeidman A,. Platelet function in the myelodysplastic syndromes. Int J Hematol. 2000; 71: 95-98.
8. Andersen PK, Gill RD,. Cox's Regression model for counting processes: a large sample study. Ann Stat. 1982; 10: 1100-1120.
9. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis- stimulating protein, for chronic ITP. N Engl J Med. 2006; 355: 1672-1681.
10. Fenaux P, Kantarjian HM, Muus P, et al. Update of an open-label extension study evaluating the long-term safety and efficacy of romiplostim in thrombocytopenic patients with myelodysplastic syndromes (MDS). Blood (ASH Annual Meeting Abstracts). 2011; 118. Abstract 2772.
11. Greenberg PL, Garcia-Manero G, Moore M, et al. A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome (MDS) receiving decitabine. Leuk Lymphoma. 2012; 54: 321-328.
12. Kantarjian H, Fenaux P, Sekeres MA, et al. Phase 1/2 study of AMG 531 in thrombocytopenic patients (pts) with low-risk myelodysplastic syndrome (MDS): update including extended treatment [abstract]. Blood (ASH Annual Meeting Abstracts). 2007; 110. Abstract 250.
13. Kantarjian H, Giles F, Fenaux P, et al. Evaluating safety and efficacy of AMG 531 for the treatment of thrombocytopenic patients with myelodysplastic syndrome (MDS): preliminary results of a phase 1/2 study [abstract]. J Clin Oncol. 2007; 25 (18S). Abstract 7032.
14. Wang ES, Lyons RM, Larson RA, et al. A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide [serial online]. J Hematol Oncol. 2012; 5: 71.
15. Sekeres MA, Kantarjian H, Fenaux P, et al. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. Cancer. 2011; 117: 992-1000.
16. Heddle NM, Cook RJ, Webert KE, et al. Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies. Transfusion. 2003; 43: 742-752.
17. Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto, N Engl J Med. 1997; 337: 1870-1875.
18. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006; 108: 419-425.
19. Vardiman JW, Harris NL, Brunning RD,. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002; 100: 2292-2302.
20. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114: 937-951.
21. Kaplan EL, Meier P,. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
22. Cox DR,. Regression models and life-tables. J R Stat Soc. 1972; 34: 187-220.
23. Stasi R, Murali M, Michel M, et al. Evaluation of bleeding-related episodes in patients with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care. Int J Hematol. 2012; 96: 26-33.
24. Weitz I, Sanz MA, Henry D, et al. A novel approach to the evaluation of bleeding-related episodes in patients with chronic immune thrombocytopenia. Curr Med Res Opin. 2012; 28: 789-796.
25. Harker LA, Marzec UM, Hunt P, et al. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood. 1996; 88: 511-521.
26. Harker LA, Hunt P, Marzec UM, et al. Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. Blood. 1996; 87: 1833-1844.
27. Ninos JM, Jefferies LC, Cogle CR, et al. The thrombopoietin receptor, c-Mpl, is a selective surface marker for human hematopoietic stem cells [abstract]. J Transl Med. 2006; 4: 9.
28. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89: 2079-2088.